Evolus Receives Acceptance of FDA BLA Resubmission for DWP-450
August 29, 2018 08:01 ET
|
Evolus
IRVINE, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the acceptance of its resubmission of its Biologics License...
Evolus Granted Approval of DWP-450 by Health Canada
August 17, 2018 08:01 ET
|
Evolus
IRVINE, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced that Health Canada has granted approval of DWP-450...
Evolus Expands Role of Chief Medical Officer Rui Avelar, MD with Appointment as Head of R&D
August 15, 2018 08:05 ET
|
Evolus
IRVINE, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the appointment of Chief Medical Officer Rui Avelar, MD, as...
Evolus, Inc. Announces Full Exercise and Closing of Underwriters’ Overallotment Option
August 15, 2018 08:01 ET
|
Evolus
IRVINE, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) today announced that the underwriters of Evolus’ previously announced public offering that initially closed...
Evolus Reports Second Quarter 2018 Financial Results
August 02, 2018 07:30 ET
|
Evolus
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today reported financial results for the second quarter ended June 30, 2018....
Evolus Announces Early Resubmission to the FDA of its Biologics License Application for DWP-450
August 02, 2018 07:25 ET
|
Evolus
BLA Resubmission to be Formally Filed Today Commercial Launch Planned for Spring 2019 IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic...
Evolus to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018
July 26, 2018 16:01 ET
|
Evolus
IRVINE, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced that it will release 2018 second...
Evolus, Inc. Announces Pricing of Public Offering of Common Stock
July 18, 2018 22:20 ET
|
Evolus
IRVINE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today the pricing of its public offering of 4,000,000 shares of common stock at a public offering...
Evolus, Inc. Announces Proposed Public Offering of Common Stock
July 16, 2018 16:01 ET
|
Evolus
IRVINE, Calif., July 16, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...
Clinical Overview of PrabotulinumtoxinA for the Investigational Treatment of Frown Lines to Be Featured During Summer Cosmetic Bootcamp 2018
June 22, 2018 09:33 ET
|
Evolus
IRVINE, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the presentation of a...